Multiple myeloma treatment is shifting toward precision medicine, where care is tailored to each individual patient instead of broad risk groups.
A new artificial intelligence tool called CORAL-histomorph can analyze standard bone marrow biopsy images and predict key genetic abnormalities—such as the 11;14 translocation—with over 90% accuracy. This is significant because it removes the need for complex genomic testing in some cases.
The system goes further by combining biopsy findings with clinical and treatment data to suggest the most effective therapy for a specific patient or estimate how well a planned treatment may work. It is especially useful in settings where advanced genetic testing is not available, as it can infer genetic information from imaging based on patterns learned from thousands of prior cases.
Although still in the research stage, CORAL is designed to support doctors in making better treatment decisions. It could help avoid unnecessary aggressive therapy in low-risk patients while identifying those who may need more intensive approaches. Experts believe that AI-driven personalization like this could play a key role in improving outcomes and moving closer to potential cures in multiple myeloma.